Immatics N.V. – Filings and Transcripts

NASDAQ: IMTX
Share price (6/4/26): $10.18
Market cap (6/4/26): $1.365 billion

Warning: Large portions of this site require JavaScript enabled in order to function properly. Please make sure JavaScript is enabled in your browser.

Please let us know at support@bamsec.com if you have any questions or concerns.

Search in Documents

Key Exhibits

External Links

Financials Filter

ended 12/31/25 FY 2025

ended 12/31/24 FY 2024

ended 12/31/23 FY 2023

ended 12/31/22 FY 2022

ended 12/31/21 FY 2021

Prospectuses and Registrations Filter

Prospectus supplement for primary offering

Prospectus supplement for primary offering

Registration of securities for employees

Removal from listing

Shelf registration

Ownership Filter

T. Rowe Price Investment Management, Inc.

Rtw Investments, LP

The Toronto Dominion Bank

Vestal Point Capital, LP

Edelman Joseph, Perceptive Advisors LLC, Perceptive Life Sciences Master Fund Ltd

News Filter

Convening Notice of the Annual General Meeting of Immatics N.V

Presents Clinical Activity of IMA203CD8 PRAME Cell Therapy in Hard-To-Treat Gynecologic Cancers at 2026 ASCO Annual Meeting

Preliminary Note

Announces Four Upcoming Oral Presentations Across Its Clinical Cell Therapy and Bispecific Portfolio at 2026 ASCO Annual Meeting

PRAME-directed Cell Therapy Using Immatics’ TCR Induces Deep and Durable Remission in Pediatric Patient With Advanced Metastatic Nephroblastoma

Proxies

No filings in this category.

Other Filter

Notice of effectiveness

Correspondence with the SEC

Letter from the SEC

Notice of effectiveness

Correspondence with the SEC